Jun 2026 (Q1 FY26) — Aug 5, 2026
RxSight, Inc. Q2 FY26 — Alcon Strategic Collaboration and Leadership Transition
Read the full callRxSight (RXST) earnings
- Jun 2026
- Jun 2026 (Q1 FY26)
- Dec 2025
RxSight earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 33.7 | +0.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -40.8 | +0.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -12.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$4.69 +3.99% · +$0.18
Performance −43.1% 1Y
1Y: $8.24 on 17 Oct 2025 → $4.69. High $13.09 (11 Dec 2025), low $4.51 (16 Oct 2026).
- Previous close
- $4.51
- 52-week range
- $4.51 – $13.09
- One year
- −45.02%
Overview
- Symbol
- RXST
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
RxSight earnings calls (RXST)
Financials
What the filings say
Net profit, year on year: −3% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 35 | 40 | 38 | 34 | 30 | 33 | 31 | 34 |
| Expenses | — | — | — | 8 | — | — | — | 8 |
| Operating profit | -9 | -9 | -11 | -14 | -12 | -11 | -18 | -14 |
| Operating margin | −26.1% | −21.5% | −28.2% | −41.6% | −40.1% | −34.8% | −57.7% | −40.8% |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -6 | -6 | -8 | -12 | -10 | -9 | -16 | -12 |
| Tax rate | −0.2% | −0.2% | −0.2% | −0.3% | −0.1% | −0.1% | −0.0% | −0.7% |
| Net profit | -6 | -6 | -8 | -12 | -10 | -9 | -16 | -12 |
| EPS ($ per share) | -0.16 | — | -0.20 | -0.29 | -0.24 | — | -0.38 | -0.29 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -431 | -479 | -546 | -595 | -622 | -661 |
| Total liabilities | 45 | 54 | 60 | 22 | 37 | 36 |
| Fixed assets | 13 | 11 | 10 | 11 | 12 | 13 |
| Investments | 55 | 135 | 94 | 117 | 221 | 208 |
| Total assets | 101 | 193 | 150 | 183 | 319 | 312 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -35 | -45 | -59 | -42 | -17 | -16 |
| Cash from investing | 16 | -82 | 40 | -22 | -99 | 17 |
| Cash from financing | 25 | 137 | 6 | 62 | 123 | 2 |
| Net cash flow | 6 | 11 | -13 | -2 | 7 | 3 |
| Capital expenditure | -3 | -2 | -2 | -5 | -5 | -4 |
| Free cash flow | -38 | -47 | -61 | -46 | -22 | -19 |
Insider filings
23 filings between Feb 28, 2026 and Sep 15, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$118.0K
4 sales by 4 insiders
Compensation
not trading decisions- 9
- Award — granted as compensation
- 8
- Option exercise — converted options into shares
- 2
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Wilterding Mark | — | $54.0K | Sep 2, 2026 |
| Kurtz Ronald M MD | — | $35.5K | Sep 2, 2026 |
| Weinberg Eric | — | $14.2K | Sep 2, 2026 |
| Goldshleger Ilya | — | $14.2K | Sep 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Weinberg Eric See remarks | Option exercise | 35,168 | $152.6K |
| Sep 2, 2026 | Weinberg Eric See remarks | Sale | 2,041 | $14.2K |
| Sep 2, 2026 | Wilterding Mark Chief Financial Officer | Sale | 7,765 | $54.0K |
| Sep 2, 2026 | Goldshleger Ilya Chief Operating Officer | Sale | 2,041 | $14.2K |
| Sep 2, 2026 | Kurtz Ronald M MD Chief Medical Officer | Sale | 5,100 | $35.5K |
| Aug 31, 2026 | Wilterding Mark Chief Financial Officer | Option exercise | 20,441 | — |
| Aug 31, 2026 | Weinberg Eric See remarks | Option exercise | 5,370 | — |
| Aug 31, 2026 | Kurtz Ronald M MD Chief Medical Officer | Option exercise | 13,425 | — |
| Aug 31, 2026 | Goldshleger Ilya Chief Operating Officer | Option exercise | 5,370 | — |
| Jun 17, 2026 | Maniar Shweta Director | Award | 37,037 | — |
| Jun 17, 2026 | COHEN RAYMOND W Director | Award | 30,864 | — |
| Jun 17, 2026 | Fountain Tamara Director | Award | 37,037 | — |
| Jun 17, 2026 | Tammenoms Bakker Juliet Director | Award | 37,037 | — |
| Jun 17, 2026 | Andrews Julie Director | Award | 37,037 | — |
| Jun 17, 2026 | LINK WILLIAM J PHD Director | Award | 37,037 | — |
| Jun 17, 2026 | Warner Robert Keith Director | Award | 37,037 | — |
| Jun 17, 2026 | Corley Jesse Anderson Director | Award | 37,037 | — |
| Jun 17, 2026 | PALMISANO ROBERT J Director | Award | 37,037 | — |
| Apr 17, 2026 | Goldshleger Ilya Chief Operating Officer | Option exercise | 12,489 | $51.6K |
| Feb 28, 2026 | Wilterding Mark Chief Financial Officer | Tax withheld | 8,068 | $61.4K |
| Feb 28, 2026 | Gaines Scott Chief Customer Officer | Tax withheld | 2,580 | $19.6K |
| Feb 28, 2026 | Wilterding Mark Chief Financial Officer | Option exercise | 20,441 | — |
| Feb 28, 2026 | Gaines Scott Chief Customer Officer | Option exercise | 6,261 | — |
| Sep 25, 2025 | Goldshleger Ilya See remarks | Option exercise | 8,349 | $34.5K |
| Sep 25, 2025 | Goldshleger Ilya See remarks | Option exercise | 15,096 | $65.5K |
| Jul 31, 2025 | COHEN RAYMOND W Director | Award | 35,668 | $0 |
| Jun 3, 2025 | LINK WILLIAM J PHD Director | Award | 10,752 | — |
| Jun 3, 2025 | Fountain Tamara Director | Award | 10,752 | — |
| Jun 3, 2025 | Corley Jesse Anderson Director | Award | 10,752 | — |
| Jun 3, 2025 | Warner Robert Keith Director | Award | 10,752 | — |
| Jun 3, 2025 | Maniar Shweta Director | Award | 10,752 | — |
| Jun 3, 2025 | PALMISANO ROBERT J Director | Award | 10,752 | — |
| Jun 3, 2025 | Andrews Julie Director | Award | 10,752 | — |
| Jun 3, 2025 | Tammenoms Bakker Juliet Director | Award | 10,752 | — |
| Jun 2, 2025 | Weinberg Eric See remarks | Option exercise | 188,002 | $738.8K |
| Apr 14, 2025 | Thunen Shelley B See remarks | Option exercise | 7,792 | $33.8K |
| Mar 12, 2025 | Fountain Tamara Director | Sale 10b5-1 plan | 7,000 | $180.0K |
| Jan 22, 2025 | Maniar Shweta Director | Sale 10b5-1 plan | 3,519 | $108.6K |
| Jan 16, 2025 | Corley Jesse Anderson Director | Purchase | 1,767 | $55.0K |
| Jan 15, 2025 | Corley Jesse Anderson Director | Purchase | 1,443 | $45.0K |
| Nov 29, 2024 | Goldshleger Ilya See remarks | Option exercise 10b5-1 plan | 3,105 | $46.8K |
| Nov 29, 2024 | Goldshleger Ilya See remarks | Sale 10b5-1 plan | 3,105 | $143.1K |
| Nov 26, 2024 | Maniar Shweta Director | Sale 10b5-1 plan | 3,782 | $173.5K |
| Nov 26, 2024 | Goldshleger Ilya See remarks | Sale 10b5-1 plan | 3,100 | $142.2K |
| Nov 26, 2024 | Goldshleger Ilya See remarks | Option exercise 10b5-1 plan | 3,100 | $46.7K |
| Nov 22, 2024 | Goldshleger Ilya See remarks | Option exercise 10b5-1 plan | 3,100 | $46.7K |
| Nov 22, 2024 | Goldshleger Ilya See remarks | Sale 10b5-1 plan | 3,100 | $139.5K |
| Nov 18, 2024 | Goldshleger Ilya See remarks | Option exercise 10b5-1 plan | 3,100 | $46.7K |
| Nov 18, 2024 | Goldshleger Ilya See remarks | Sale 10b5-1 plan | 33 | $1.5K |
| Nov 18, 2024 | Goldshleger Ilya See remarks | Sale 10b5-1 plan | 3,067 | $138.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for RxSight, Inc.
Free account. Everything above stays public.
Write why you follow RxSight, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading